CD274 and neoplasm: Regarding its ligand PD-L1, one study indicates that PD-L1 targeting may be beneficial in PD-L1-negative tumors and that this is mediated through the direct binding of monoclonal antibodies to tumor-induced PD-L1 expression on the NK cells [20].